TheKi-67nuclearantigenisassociatedwithcellproliferationandfoundthroughoutthecellcycle;thoughnotinG0phase(1,2).TheassessmentofKi-67proliferationinbreastcancershasshowntheKi-67labellingindexisanimportantpredictorofsurvival(3).
MicroscopicevaluationofmitoticfiguresonH&Eisaroutineprocedureintheassessmentofthetumorgrades(4).However,thecountingofmitosisismanualandtimeconsumingwithassorteddifficultiesaswellasvariABIlitiesbetweeninterobserverassessments(5).HistoneH3phosphorylationatSerine10(pHH3)isinassociationwithmitoticchromatincondensationinlateG2andMphaseofthecellcycle.pHH3candistinguishmitosisfromapoptoticnuclei(6).TheimmunohistochemicalstainingofSerine10-pHH3hasbeenreportedtobecomparabletomitoticfiguresintheH&Esection(7-10).
Immunohistochemicalstudieshaveshownimmunostainingusinganti-Ki-67andanti-pHH3antibodiesprovidedimprovedpredictionofrecurrenceoftumorsandmaybecomeeffectiveancillarytoolsindecidingonoptimaltherapeuticmanagement(11).OtherstudieshaveshownKi-67andpHH3canbeusefulinseparatingmalignantmelanomafrombenignnevi(12).
| Format | Predilute |
|---|---|
| Volume | 6.0ml |
| IntendedUse | IVD |
| ByLetter | K |
| Clone | MIB-1BC37 |
| Source | MouseMonoclonal,RabbitMonoclonal |
References:
1.GerdesJ,etal.Cellcycleanalysisofacellproliferation-associatedhumannuclearantigendefinedbythemonoclonalantibodyKi-67.JImmunol.1984Oct;133(4):1710-5.
2.McCormickD,etal.DetectionoftheKi-67antigeninfixedandwaxembeddedsectionswiththemonoclonalantibodyMIB1.Histopathology.1993Apr;22(4):355-60.
3.PinderSE,etal.AssessmentofthenewproliferationMarkerMIB1inbreastcarcinomausingimageanalysis:associationswithotherprognosticfactorsandsurvival.BrJCancer.1995Jan;71(1):146-9.
4.JanninkI,etal.Comparisonoftheprognosticvalueoffourmethodstoassessmitoticactivityin186invasivebreastcancerpatients:classicalandrandommitoticactivityassessmentswithcorrectionforvolumepercentageofepithelium.HumPathol.1995Oct;26(10):1086-92.
5.YadavKS,etal.Assessmentofinterobservervariabilityinmitoticfigurecountingindifferenthistologicalgradesoforalsquamouscellcarcinoma.JContempDentPract.2012May1;13(3):339-44.
6.LadsteinRG,etal.PrognosticimportanceofthemitoticmarkerphosphohistoneH3incutaneousnodularmelanoma.JInvestDermatol.2012Apr;132(4):1247-52.
7.TharejaS,etal.Analysisoftumormitoticrateinthinmetastaticmelanomascomparedwiththinmelanomaswithoutmetastasisusingboththehematoxylinandeosinandantiphosphohistone3IHCstain.AmJDermatopathol.2014Jan;36(1):64-7.
8.IkenbergK,etal.Immunohistochemicaldualstainingasanadjunctinassessmentofmitoticactivityinmelanoma.JCutanPathol.2012Mar;39(3):324-30.
9.CasperDJ,etal.Useofanti-phosphohistoneH3immunohistochemistrytodeterminemitoticrateinthinmelanoma.AmJDermatopathol.2010Oct;32(7):650-4.
10.FultonR,MD,PhD,TachaD,PhD.UseofaNovelRabbitMonoclonalPhospho-HistoneH3(Ser10)versusH&EMitoticCountinMelanoma.USCAP2016,PosterSessionIV#96.
11.UguenA.etal.Immunostainingofphospho-histoneH3andKi-67improvesreproducibilityofrecurrenceriskassessmentofgastrointestinalstromaltumors.VirchowsArch.2015Jul;467(1):47-54.
12.NasrMR,El-Zammar.ComparisonofpHH3,Ki-67,andsurvivinimmunoreactivityinbenignandmalignantmelanocyticlesions.AmJDermatopathol.2008Apr;30(2):117-22.
13.CenterforDiseaseControlManual.Guide:SafetyManagement,NO.CDC-22,Atlanta,GA.April30,1976“DecontaminationofLaboratorySinkDrainstoRemoveAzideSalts.”
14.ClinicalandLaboratoryStandardsInstitute(CLSI).ProtectionofLaboratoryWorkersfromOccupationallyAcquiredInfections;ApprovedGuideline-FourthEditionCLSIdocumentM29-A4Wayne,PA2014.
